Voltar
Artigo Acesso aberto Revisado por pares
BIBTEX RIS

Sorin BicarbonTM bileaflet valve: a 9.8-year experience. Clinical performance of the prosthesis after heart valve replacement in 587 patients

2008; Oxford University Press; Volume: 8; Issue: 2 Linguagem: Inglês

10.1510/icvts.2008.183590

ISSN

1569-9293

Autores

Kyriakos Spiliopoulos, Ayman Haschemi, Paris Parasiris, B. M. Kemkes,

Tópico(s)

Cardiac Structural Anomalies and Repair

Resumo

To determine early and mid-term clinical performance of the Sorin Bicarbon bileaflet prosthesis.Between January 1993 and October 2000, 1092 patients received at least one Sorin Bicarbon prosthesis. Six hundred and fourteen of those fulfilled the inclusion criteria and were contacted by mail and/or telephone interview. Five hundred and eighty-seven (95.6%) patients aged 16.2-85.9 years (mean 61.5 years), 368 males and 219 females, were available for clinical evaluation. Four hundred and fifteen patients underwent aortic--(AVR) (70.7%), 122 mitral--(MVR) (20.8%), 50 double valve replacement (DVR) (8.5%). 86.4% of the patients were in NYHA functional class III or IV. Cumulative duration of follow-up is 2474 patient-years (py) with a maximum of 9.8 years.Overall hospital mortality (30 days) rate was 4.2% (n=26). The early mortality rate was significantly higher in females and patients older than 70 years (P or=70 years) as an independent mortality risk factor (P=0.03). Valve related complications were thromboembolism: 1.33%/patient-years (n=34), anticoagulant related hemorrhage: 1.21%/patient-years (n=30), bacterial endocarditis: 0.16%/patient-years (n=4), reoperation: 0.69%/patient-years (n=17), paravalvular leak: 0.69%/patient-years (n=17). No structural dysfunction of the prosthesis has been reported. Actuarial freedom from complications at 9.8 years was: thromboembolism 86.7%, major hemorrhage 92.3%, prosthetic valve endocarditis 99.1% and reoperation 95.8%.Sorin Bicarbon prosthesis provides excellent clinical results and mid-term survival with very low complication rates comparable with those of other bileaflet prostheses currently in use.

Referência(s)